Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.
Adoptive Transfer
Animals
Antigens, CD34
/ genetics
Bone Marrow Cells
/ immunology
Female
Fibroblasts
/ immunology
Gene Expression
HLA Antigens
/ genetics
Humans
Hyperplasia
/ etiology
Immunocompromised Host
Janus Kinase 2
/ genetics
Lipopolysaccharide Receptors
/ genetics
Megakaryocytes
/ immunology
Mice
Mice, Inbred NOD
Mice, SCID
Monocytes
/ immunology
Mutation
Primary Myelofibrosis
/ etiology
Splenomegaly
/ etiology
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
01
2019
accepted:
10
09
2019
entrez:
1
10
2019
pubmed:
1
10
2019
medline:
13
3
2020
Statut:
epublish
Résumé
To confirm that neoplastic monocyte-derived collagen- and fibronectin-producing fibrocytes induce bone marrow (BM) fibrosis in primary myelofibrosis (PMF), we injected PMF BM-derived fibrocyte-precursor CD14+/CD34- monocytes into the tail vein of NOD-SCID-γ (NSG) mice. PMF BM-derived CD14+/CD34- monocytes engrafted and induced a PMF-like phenotype with splenomegaly, myeloid hyperplasia with clusters of atypical megakaryocytes, persistence of the JAK2V617F mutation, and BM and spleen fibrosis. As control we used normal human BM-derived CD14+/CD34- monocytes. These monocytes also engrafted and gave rise to normal megakaryocytes that, like PMF CD14+/CD34--derived megakaryocytes, expressed HLA-ABC and human CD42b antigens. Using 2 clonogenic assays we confirmed that PMF and normal BM-derived CD14+/CD34- monocytes give rise to megakaryocyte colony-forming cells, suggesting that a subpopulation BM monocytes harbors megakaryocyte progenitor capacity. Taken together, our data suggest that PMF monocytes induce myelofibrosis-like phenotype in immunodeficient mice and that PMF and normal BM-derived CD14+/CD34- monocytes give rise to megakaryocyte progenitor cells.
Identifiants
pubmed: 31569199
doi: 10.1371/journal.pone.0222912
pii: PONE-D-19-02820
pmc: PMC6768666
doi:
Substances chimiques
Antigens, CD34
0
Cd14 protein, mouse
0
HLA Antigens
0
Lipopolysaccharide Receptors
0
Jak2 protein, mouse
EC 2.7.10.2
Janus Kinase 2
EC 2.7.10.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0222912Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207204
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Calcif Tissue Int. 2005 Mar;76(3):222-30
pubmed: 15692727
Blood. 2014 May 29;123(22):e123-33
pubmed: 24740812
Mol Med. 1994 Nov;1(1):71-81
pubmed: 8790603
Ann Hematol. 2006 Apr;85(4):226-32
pubmed: 16421727
J Exp Med. 2016 Aug 22;213(9):1723-40
pubmed: 27481130
Methods. 2014 Nov;70(1):46-58
pubmed: 25242720
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):25-36
pubmed: 30580568
Blood. 2015 Apr 23;125(17):2605-13
pubmed: 25762175
F1000Res. 2017 May 26;6:748
pubmed: 28663787
Nat Rev Immunol. 2011 Jun;11(6):427-35
pubmed: 21597472
Ann Intern Med. 1980 Jun;92(6):857-8
pubmed: 7387029
Haematologica. 2005 Aug;90(8):1128-32
pubmed: 16079113
Blood. 2005 May 1;105(9):3493-501
pubmed: 15665119
Cytometry. 2000 Dec 1;41(4):308-15
pubmed: 11084616
Cell Immunol. 1994 Jun;156(1):191-211
pubmed: 8200035
Br J Haematol. 2012 May;157(4):413-25
pubmed: 22463701
Scand J Immunol. 1996 Aug;44(2):143-9
pubmed: 8711427
Invest New Drugs. 2011 Oct;29(5):818-26
pubmed: 20372971
Blood. 2008 Feb 15;111(4):1862-5
pubmed: 18029552
Blood Rev. 2014 Jan;28(1):31-40
pubmed: 24476957
Blood. 2001 Apr 1;97(7):2023-30
pubmed: 11264167
PLoS One. 2011;6(10):e25595
pubmed: 22022418